FDA approves Biogen's $56,000 drug for Alzheimer's
The Food and Drug Administration of the US approved on Monday Biogen Inc's Aducanumab to treat Alzheimer's disease amidst the controversy of its efficacy.
Source: industryleadersmagazine.com